• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)

Posted on: Wednesday, 24 June 2009, 13:41 CDT

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreement, KBI joins the Vendor Network as a U.S.-based pre-approved cell line generation partner for licensees of the PER.C6(R) cell lines.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. KBI, based in Durham, NC, applies cell line generation, extensive protein characterization, manufacturing process development and clinical biomanufacturing capabilities to accelerate and optimize its clients' drug development programs. This comprehensive and integrated suite of services enables clients to bring drugs to market faster and more efficiently. KBI is recognized for its track record in advancing its clients' drug programs by developing scalable, robust processes that result in more stable, active products.

Joseph McMahon, President and CEO of KBI Biopharma notes, "We recognize the significant market interest in and adoption of this technology and are very pleased to now offer cell line generation using the PER.C6(R) cell line." Mr. McMahon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that Crucell and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network."

KBI is now proud to offer the PER.C6(R) technology as part of its extensive capabilities in cell line development.

Other terms of the agreement were not disclosed.

About KBI Biopharma, Inc.

KBI Biopharma, located in Durham, NC, is a leading contract development organization for the biopharmaceutical industry, working with companies across the globe focused on protein-based products. KBI delivers expert and integrated biophysical and biochemical protein characterization, formulation and process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API's). For additional information about KBI Biopharma please visit www.kbibiopharma.com.

PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(R) human cell line with a proprietary process technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.

SOURCE KBI Biopharma, Inc.

Source: PR Newswire

More News in this Category